CD47 and neoplasm: Competitive binding of anti-CD47 antibodies to CD47 on tumor cells blocks the interaction between CD47 and SIRPα on CAR-Ms, thereby reversing macrophage immune suppression and significantly enhancing the phagocytic activity of CAR-Ms.